{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:47:21Z","timestamp":1784137641527,"version":"3.55.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015235","name":"Supernus Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015235","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020357","name":"Amneal Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003183","name":"National Pancreas Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003183","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.prdoa.2022.100174","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T02:24:20Z","timestamp":1671416660000},"page":"100174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature"],"prefix":"10.1016","volume":"8","author":[{"given":"Stuart H.","family":"Isaacson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Richard B.","family":"Dewey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Pahwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Kremens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prdoa.2022.100174_b0005","unstructured":"APOKYN Prescribing information. Available for download at https:\/\/www.apokyn.com\/assets\/APOKYN_PI.pdf, (2022)."},{"issue":"5","key":"10.1016\/j.prdoa.2022.100174_b0010","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/mds.870130505","article-title":"A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease","volume":"13","author":"Dewey","year":"1998","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.prdoa.2022.100174_b0015","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/archneur.58.9.1385","article-title":"A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events","volume":"58","author":"Dewey","year":"2001","journal-title":"Arch. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.prdoa.2022.100174_b0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jns.2007.03.013","article-title":"Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose","volume":"258","author":"Pahwa","year":"2007","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.prdoa.2022.100174_b0025","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.coph.2006.07.004","article-title":"Making a case for domperidone in the treatment of gastrointestinal motility disorders","volume":"6","author":"Ahmad","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"issue":"3","key":"10.1016\/j.prdoa.2022.100174_b0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/WNF.0000000000000082","article-title":"Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses","volume":"38","author":"Bhidayasiri","year":"2015","journal-title":"Clin. Neuropharmacol."},{"issue":"4","key":"10.1016\/j.prdoa.2022.100174_b0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1353-8020(97)00032-1","article-title":"Domperidone is superior to ondansetron in acute apomorphine challenge in previously untreated parkinsonian patients - a double blind study","volume":"3","author":"Arnold","year":"1997","journal-title":"Parkinsonism Relat. Disord."},{"issue":"Suppl 1","key":"10.1016\/j.prdoa.2022.100174_b0040","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.parkreldis.2016.11.017","article-title":"Practical management of adverse events related to apomorphine therapy","volume":"33","author":"Bhidayasiri","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"issue":"2","key":"10.1016\/j.prdoa.2022.100174_b0045","first-page":"137","article-title":"Dopamine receptor antagonists","volume":"1","author":"Smith","year":"2012","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.prdoa.2022.100174_b0050","doi-asserted-by":"crossref","unstructured":"American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults, J Am Geriatr Soc 60(4) (2012) 616-31.","DOI":"10.1111\/j.1532-5415.2012.03923.x"},{"issue":"5","key":"10.1016\/j.prdoa.2022.100174_b0055","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.parkreldis.2012.01.001","article-title":"Apomorphine injections: predictors of initial common adverse events and long term tolerability","volume":"18","author":"Ondo","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"issue":"11","key":"10.1016\/j.prdoa.2022.100174_b0060","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.parkreldis.2014.08.010","article-title":"Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection","volume":"20","author":"Hauser","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"issue":"8","key":"10.1016\/j.prdoa.2022.100174_b0065","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.parkreldis.2014.04.008","article-title":"Sustained efficacy of apomorphine in Japanese patients with advanced Parkinson's disease","volume":"20","author":"Hattori","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.prdoa.2022.100174_b0070","article-title":"Apomorphine hydrochloride injection treatment initiations in the presence and absence of an antiemetic in people with Parkinson Disease (Abstract)","author":"Happel","year":"2022","journal-title":"Mov. Disord."}],"container-title":["Clinical Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112522000457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112522000457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:46:57Z","timestamp":1762912017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112522000457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":14,"alternative-id":["S2590112522000457"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2022.100174","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2022.100174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100174"}}